. . . "approved"@en . . . "* 60 L/kg [healthy adults]"@en . "It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney."@en . . . . . "# Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12904852 # Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18326136 # Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Feb 26;:1-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18298873"@en . "95 to 99%, primarily to serum albumin and hemoglobin"@en . "2078-54-8"@en . . "Initial distribution phase t1/2α=1.8-9.5 minutes. Second redistirubtion phase t1/2β=21-70 minutes. Terminal elimination phase t1/2γ=1.5-31 hours. "@en . . . . . "2,6-Bis(1-methylethyl)phenol"@en . "Propofol"@en . . . . . . "Propofolum"@en . . . . . . . "Humans and other mammals"@en . . . "Overdosage may increase pharmacologic and adverse effects or cause death.

IV LD50=53 mg/kg (mice), 42 mg/kg (rats). Oral LD50 (as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)

"@en . "Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes. "@en . . "Rapinovet"@en . . . . . . . . . . . . . . . . . . . . . . . . . "Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries."@en . . . . . . . "Disoprofol"@en . . "John R. Carpenter, \"Propofol-based anesthetic and method of making same.\" U.S. Patent US6150423, issued May, 1977."@en . . "Disoprivan"@en . " "@en . . "The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors."@en . "* 23 - 50 mL/kg/min * 1.6 - 3.4 L/min [70 Kg adults]"@en . . . . "Diprivan"@en . "investigational"@en . . "Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus. "@en . . . . "2,6-Diisopropylphenol"@en . . . . "Propofol"@en .